Anavex Life Sciences Corp (AVXL)

[falconer66a]

If So, Great!

I am expecting major share price appreciation well before the results come in.

The market is forward looking, emotional and likes to value companies on future potential.

Good question. Will the market begin to see and value Anavex’s future potential before any trial results appear? Might the accumulation of presented science, in the manner of the data to appear at the up-coming CTAD event, cause a price-elevating “gotta get in on this” perspective? Could the science, finally, appear in multiple, substantiated forms that overwhelm the “Can’t treat Alzheimer’s no way” crowd?

Somehow, might Anavex start to be perceived as the next big medical treatment thing? As I’ve described before, the things to prompt that, before any final trail results appear, will be accounts in the media of, say, mothers of Rett daughters who exclaim how their little girls are starting to live normal lives, “Now that they are taking THAT drug.” Then, throw in a few similar accounts of Australians no longer forgetting what day it is, or no longer wondering around the house or yard at weird hours; or accounts of Spaniards with Parkinson’s who no longer have quivering muscles. Those Anavex stories are ones that will be told. Human interest stories of the highest sort — leading eventually to AVXL share prices of the highest level.

In every case, it’s the human element that controls. Already, lab mice with Rett genes and symptoms have had profound therapeutic outcomes. Lab rats with human Alzheimer’s genes have had remarkable resolutions; along with a handful of humans in the Phase 1 safety and tolerability trial Down Under. When a bunch of Spaniards with Parkinson’s and Australians with Alzheimer’s, along with a few dozen little girls with Rett syndrome all reveal positive therapeutic outcomes, those will be hard to keep hidden.

May the market (and news reporters and writers) then take note. All of us, here, will benefit.